Method and composition for improvement of glucose regulation and insulin effect through alimentation

FIELD: medicine.

SUBSTANCE: invention is related to alimentation, in particular - to a method and composition for improvement of glucose and insulin balance. Proposed is a compound that includes: a protein source, a fat source and a carbohydrate source, the protein source to the fat source ratio being approximately 1:1:1, each source accounting for 15% - 45% of the total calorie content of the compound. The fat source accounts for approximately over 2% of the total calorie content of the composition in the form of linoleic acid (18:2). According to an alternative version, the food compound for normalisation of insulin and glucose in the organism contains a protein source, a fat source and a carbohydrate source at a ratio of 1:1:1, each of these components accounting for approximately a third of the total calorie content of the compound. Additionally proposed are a diet for enhancement of sensitivity to insulin, a method to reduce resistivity to insulin, a method to reduce insulin levels in the plasma during after dinner time, a method to delay occurrence of insulin in one's blood and a method to increase fat clearance during after dinner time envisaging usage of the above food compound.

EFFECT: invention allows to improve glucose regulation and insulin effect.

68 cl, 34 dwg, 38 tbl

 

The text descriptions are given in facsimile form.

1. Food composition, including
A. source of protein,
B. the source of fat and
C. a source of carbohydrates,
in which the protein source and the fat source are in a ratio of about 1:1, each source contains from about 15% to about 45% of calories from total calories in the structure in which the source of fat contains approximately 2% of the total calories of the composition in the form of linoleic acid (18:2).

2. The food composition of claim 1, wherein the source of protein and a source of fat contains approximately 25% of the total calories of the composition.

3. The food composition according to claim 1, in which the protein source and the fat source contain approximately 35% of the total calories of the composition.

4. The food composition according to claim 1, in which the protein source and the fat source contain from about 20% to about 40% each of the total calories of the composition.

5. The food composition according to claim 1, in which the protein source and the fat source contain from about 25% to about 35% each of the total calories of the composition.

6. The food composition according to claim 1, in which the protein source and the fat source of sod is rat from about 30% to about 35% each of the total calories of the composition.

7. The food composition according to claim 1, in which the source of fat contains from about 2% to about 10% of the total calories of the composition in the form of linoleic acid (18:2).

8. The food composition according to claim 1, in which the source of fat contains from about 2% to about 7% of the total calories of the composition in the form of linoleic acid (18:2).

9. The food composition according to claim 1, in which the source of fat contains approximately 5% to approximately 6% of the total calories of the composition in the form of linoleic acid (18:2).

10. The food composition according to claim 1, in which the source of fat contains about 4% of the total calories of the composition in the form of linoleic acid (18:2).

11. The food composition according to claim 1, in which the source of fat contains about 5% of the total calories of the composition in the form of linoleic acid (18:2).

12. The food composition according to claim 1, in which the source of fat contains approximately 6% of the total calories of the composition in the form of linoleic acid (18:2).

13. The food composition according to claim 1, in which the source of fat contains about 7% of the total calories of the composition in the form of linoleic acid (18:2).

14. The food composition according to claim 1, in which the source of fat contains approximately 8% of the total calories of the composition in the form of linoleic acid (18:2).

15. The food composition according to claim 1, additionally comprising at least one of the following comp is required: soybean extract the clouds, partially gidralizovanny guar gum, inulin, fructooligosaccharide, galactooligosaccharide, isomaltulose, sweetener of sacrament, trehalose, lipyeow acid, 4-hydroxyisoleucine, catechin, cinnamon, banana extract, dietary Supplement product Madeglucyl, arginine, branched chain amino acids, glutamine, glutamate, fish oil, chlorogen acid, mangostan, palm oil cake, chromium, vanadium, hazel Virginia, cloves, Bay leaf, nutmeg, garlic cloves, mushrooms, baking yeast Saccharomyces cerevisiae and their combinations.

16. Food composition for normalizing insulin and glucose in the body of the individual, including
A. source of protein,
B. the source of fat and
C. a source of carbohydrates,
in which the protein source, a fat source and a source of carbohydrates are in the ratio 1:1:1, and each contains approximately one third of the total calories of the composition, and the source of fat contains approximately 2% of the total calories of the composition in the form of linoleic acid (18:2).

17. The food composition according to item 16, further comprising at least one of the following: soybean extract the clouds, partially gidralizovanny guar gum, inulin, fructooligosaccharide, galactooligosaccharide, isomaltulose, sweetener of sacrament, trehalose, lipyeow acid, 4-hydroxyisoleucine, catechin, cinnamon, extra is tons of banana, dietary Supplement product Madeglucyl, arginine, branched chain amino acids, glutamine, glutamate, fish oil, chlorogen acid, antioxidant and anti-inflammatory agent mangostan, palm oil cake, chromium, vanadium, hazel Virginia, cloves, Bay leaf, nutmeg, garlic cloves, mushrooms, baking yeast Saccharomyces cerevisiae and their combinations.

18. The food composition according to item 16, in which linoleic acid (18:2) contains from about 4% to about 7% of the total calories of the composition.

19. Food composition b, in which linoleic acid (18:2) contains from about 5% to about 6% of the total calories of the composition.

20. Diet to increase insulin sensitivity, including:
A. source of protein,
B. the source of fat and
C. a source of carbohydrates,
in which the protein source and the fat source are in a ratio of about 1:1, each source contains from about 15% to about 45% of calories from total calories in the diet, in which the source of fat contains approximately 2% of the total calories in the diet in the form of linoleic acid (18:2).

21. Diet according to claim 20, in which the protein source and the fat source each contains approximately 25% of the total calories in the diet.

22. Diet according to claim 20, in which the protein source and the fat source each contains approximately 35% of the total number of Kalo what s in the diet.

23. Diet according to claim 20, in which the protein source and the fat source each contains from about 20% to about 40% of the total calories in the diet.

24. Diet according to claim 20, in which the protein source and the fat source each contains from about 25% to about 35% of total calories in the diet.

25. Diet according to claim 20, in which the protein source and the fat source each contains from about 30% to about 35% of total calories in the diet.

26. Diet according to claim 20, in which the source of fat contains from about 2% to about 10% of the total calories in the diet in the form of linoleic acid (18:2).

27. Diet according to claim 20, in which the source of fat contains from about 4% to about 7% of total calories in the diet in the form of linoleic acid (18:2).

28. Diet according to claim 20, in which the source of fat contains approximately 5% to approximately 6% of total calories in the diet in the form of linoleic acid (18:2).

29. Diet according to claim 20, in which the source of fat contains about 4% of the total calories in the diet in the form of linoleic acid (18:2).

30. Diet according to claim 20, in which the source of fat contains about 5% of the total calories in the diet in the form of linoleic acid (18:2).

31. Diet according to claim 20, in which the source of fat contains approximately 6% of total calories in the diet in the form of linoleic acid (18:2).

32. Diet according to claim 20, in which the light source is to fat contains about 7% of total calories in the diet in the form of linoleic acid (18:2).

33. Diet according to claim 20, in which the source of fat contains approximately 8% of the total calories in the diet in the form of linoleic acid (18:2).

34. Diet claim 20, further comprising at least one of the following: soybean extract the clouds, partially gidralizovanny guar gum, inulin, fructooligosaccharide, galactooligosaccharide, isomaltulose, sweetener of sacrament, trehalose, lipyeow acid, 4-hydroxyisoleucine, catechin, cinnamon, banana extract, dietary Supplement product Madeglucyl, arginine, branched chain amino acids, glutamine, glutamate, fish oil, chlorogen acid, antioxidant and anti-inflammatory agent mangostan, palm oil cake, chromium, vanadium, hazel Virginia, cloves, Bay leaf, nutmeg, cloves, mushrooms, baking yeast Saccharomyces cerevisiae and their combinations.

35. Diet to increase insulin sensitivity, including:
A. source of protein,
B. the source of fat and
C. a source of carbohydrates,
in which the protein source, a fat source and a source of carbohydrates are in a ratio of about 1:1:1, each source contains about one third of the total number of calories in the diet and the source of fat contains approximately 2% of the total calories of the composition in the form of linoleic acid (18:2).

36. Diet p, additionally comprising at least Odie is of the following components: soy extract the clouds, partially gidralizovanny guar gum, inulin, fructooligosaccharide, galactooligosaccharide, isomaltulose, sweetener of sacrament, trehalose, lipyeow acid, 4-hydroxyisoleucine, catechin, cinnamon, banana extract, dietary Supplement product Madeglucyl, arginine, branched chain amino acids, glutamine, glutamate, fish oil, chlorogen acid, antioxidant and anti-inflammatory agent mangostan, palm oil cake, chromium, vanadium, hazel Virginia, cloves, Bay leaf, nutmeg, garlic cloves, mushrooms, baking yeast Saccharomyces cerevisiae and their combinations.

37. Diet p, in which the source includes fats linoleic acid (18:2).

38. Diet p, in which linoleic acid (18:2) contains more than about 2% of the total calories of the composition.

39. Diet p, in which linoleic acid (18:2) contains from about 2% to about 10% of the total calories of the composition.

40. Diet p, in which linoleic acid (18:2) contains from about 4% to about 7% of the total calories of the composition.

41. Diet p, in which linoleic acid (18:2) contains from about 5% to about 6% of the total calories of the composition.

42. A method of reducing resistance to insulin at the individual, including:
A. introduction he compositions containing
(i) a source of protein,
(ii) the source of the LM is s and
(iii) a source of carbohydrates,
in which the protein source and the fat source are in a ratio of about 1:1, each source contains from about 15% to about 45% of calories from total calories in the structure in which the source of fat contains approximately 2% of the total calories of the composition in the form of linoleic acid (18:2).

43. The method according to § 42, in which the individual is a mammal.

44. The method according to § 42, in which the individual is the man.

45. The method according to § 42, in which the protein source, a fat source and a source of carbohydrates are in a ratio of about 1:1:1, each source contains about one third of the total calories of the composition.

46. The method according to § 42, in which the composition additionally includes at least one of the following: soybean extract the clouds, partially gidralizovanny guar gum, inulin, fructooligosaccharide, galactooligosaccharide, isomaltulose, sweetener of sacrament, trehalose, lipyeow acid, 4-hydroxyisoleucine, catechin, cinnamon, banana extract, dietary Supplement product Madeglucyl, arginine, branched chain amino acids, glutamine, glutamate, fish oil, chlorogen acid, antioxidant and anti-inflammatory agent mangostan, palm oil cake, chromium, vanadium, hazel Virginia, cloves, Bay leaf, nutmeg, subji and garlic, mushrooms, baking yeast Saccharomyces cerevisiae and their combinations.

47. Method of delaying the appearance of glucose in the blood of the individual, including:
A. introduction to individual songs, including:
i. A. source of protein,
ii. B. the source of fat and
iii. C. a source of carbohydrates,
in which the protein source and the fat source are in a ratio of about 1:1, each source contains from about 15% to about 45% of calories from total calories of the composition, in which the source of fat contains approximately 2% of the total calories of the composition in the form of linoleic acid (18:2).

48. The method according to p in which the individual is a mammal.

49. The method according to p in which the individual is the man.

50. The method according to p, in which the protein source, a fat source and a source of carbohydrates are in a ratio of about 1:1:1, each source contains about one third of the total calories of the composition.

51. The method according to p, in which the composition additionally includes at least one of the following: soybean extract the clouds, partially gidralizovanny guar gum, inulin, fructooligosaccharide, galactooligosaccharide, isomaltulose, sweetener of sacrament, trehalose, lipyeow acid, 4-hydroxyisoleucine, catechin, cinnamon, banana extract, dietary Supplement product Madeglucyl, arginine, the amino acid is s branched chain, glutamine, glutamate, fish oil, chlorogen acid, antioxidant and anti-inflammatory agent mangostan, palm oil cake, chromium, vanadium, hazel Virginia, cloves, Bay leaf, nutmeg, garlic cloves, mushrooms, baking yeast Saccharomyces cerevisiae and their combinations.

52. A method of reducing levels of insulin in the plasma in the afternoon, including:
A. introduction to individual songs, including:
i and. source of protein,
ii. B. the source of fat and
iii. C. a source of carbohydrates,
in which the protein source and the fat source are in a ratio of about 1:1, each source contains from about 15% to about 45% of calories from total calories in the structure in which the source of fat contains approximately 2% of the total calories of the composition in the form of linoleic acid (18:2).

53. The method according to paragraph 52, in which the individual is a mammal.

54. The method according to paragraph 52, in which the individual is the man.

55. The method according to paragraph 52, in which the protein source, a fat source and a source of carbohydrates are in a ratio of about 1:1:1, each source contains about one third of the total calories of the composition.

56. The method according to paragraph 52, in which the composition additionally includes at least one of the following: soybean extract the clouds, partially gidralizovanny guar gum, the Nulin, fructooligosaccharide, galactooligosaccharide, isomaltulose, sweetener of sacrament, trehalose, lipyeow acid, 4-hydroxyisoleucine, catechin, cinnamon, banana extract, dietary Supplement product Madeglucyl, arginine, branched chain amino acids, glutamine, glutamate, fish oil, chlorogen acid, antioxidant and anti-inflammatory agent mangostan, palm oil cake, chromium, vanadium, hazel Virginia, cloves, Bay leaf, nutmeg, garlic cloves, mushrooms, baking yeast Saccharomyces cerevisiae and their combinations.

57. The way to increase the clearance of fat in the afternoon, including:
A. introduction to individual songs, including:
i. A. source of protein,
ii. B. the source of fat and
iii. C. a source of carbohydrates,
in which the protein source and the fat source are in a ratio of about 1:1, each source contains from about 15% to about 45% of calories from total calories in the structure in which the source of fat contains approximately 2% of the total calories of the composition in the form of linoleic acid (18:2).

58. The method according to § 57, in which the individual is a mammal.

59. The method according to § 57, in which the individual is the man.

60. The method according to § 57, in which the protein source, a fat source and a source of carbohydrates are in a ratio of about 1:1:1, each source content is t approximately one-third of the total number of calories in the structure.

61. The method according to § 57, in which the composition additionally includes at least one of the following: soybean extract the clouds, partially gidralizovanny guar gum, inulin, fructooligosaccharide, galactooligosaccharide, isomaltulose, sweetener of sacrament, trehalose, lipyeow acid, 4-hydroxyisoleucine, catechin, cinnamon, banana extract, dietary Supplement product Madeglucyl, arginine, branched chain amino acids, glutamine, glutamate, fish oil, chlorogen acid, antioxidant and anti-inflammatory agent mangostan, palm oil cake, chromium, vanadium, hazel Virginia, cloves, Bay leaf, nutmeg, garlic cloves, mushrooms, baking yeast Saccharomyces cerevisiae and their combinations.

62. A method of treating or preventing cardiovascular disease or other diseases, including:
A. introduction to individual songs, including:
i. A. source of protein,
ii. B. the source of fat and
iii. C. a source of carbohydrates,
in which the protein source and the fat source are in a ratio of about 1:1, each source contains from about 15% to about 45% of calories from total calories of the composition, in which the source of fat contains approximately 2% of the total calories of the composition in the form of linoleic acid (18:2).

63. The method according to item 62, in which the individual is mlec the feed.

64. The method according to item 62, in which the individual is the man.

65. The method according to item 62, in which the protein source, a fat source and a source of carbohydrates are in a ratio of about 1:1:1, each source contains about one third of the total calories of the composition.

66. The method according to item 62, in which the composition additionally includes at least one of the following: soybean extract the clouds, partially gidralizovanny guar gum, inulin, fructooligosaccharide, galactooligosaccharide, isomaltulose, sweetener of sacrament, trehalose, lipyeow acid, 4-hydroxyisoleucine, catechin, cinnamon, banana extract, dietary Supplement product Madeglucyl, arginine, branched chain amino acids, glutamine, glutamate, fish oil, chlorogen acid, antioxidant and anti-inflammatory agent mangostan, palm oil cake, chromium, vanadium, hazel Virginia, cloves, Bay leaf, nutmeg, garlic cloves, mushrooms, baking yeast Saccharomyces cerevisiae and their combinations.

67. The method according to item 62, in which the specified cardiovascular or other disease is a disease associated with diabetes.

68. The method according to item 62, in which the specified cardiovascular illness or condition selected from the group including: cardiovascular disease, disease of the coronary vessels, coronary heart disease, is infarct infarction, disease peripheral vascular, cerebrovascular disease, stroke, metabolic syndrome, retinopathy, blindness, hypertension, thrombosis and inflammation.



 

Same patents:

FIELD: medicine.

SUBSTANCE: in formula (I) , the ring A represents 6-members aryl or 5-6-members heteroaryl containing 1-2 heteroatoms selected from nitrogen and sulphur; Q means C3-8 cycloalkyl, 5-6-members heterocycle containing 1 heteroatom selected from oxygen, nitrogen or sulphur, C1-6 alkyl or C2-6 alkenyl; the ring T represents 5, 6, 9 or 10-members heteroaryl or 9-members heterocycle optionally additionally substituted by 1-3 heteroatoms independently selected from nitrogen or sulphur. The values of other substitutes are specified in the patent claim. Also, the invention refers to methods for preparing oxime derivatives of general formula (I), to pharmaceutical compositions containing the compound of the invention as an active ingredient and to applications of the compounds of the invention in preparing a drug.

EFFECT: compounds of the invention exhibit properties of a glucokinase activator.

33 cl, 1499 ex

FIELD: chemistry.

SUBSTANCE: invention relates to novel compounds - benzoquinone derivatives of formula (I): , where each of R1 and R2 is O-C(O)phenyl; where the phenyl is substituted with 1 substitute selected from halide, nitro, C1-C6 alkyl or C1-C6 alkoxy, and pharmaceutically acceptable salts thereof.

EFFECT: low activity of pancreatic lipase based on compounds of the said formula.

6 cl, 3 tbl, 23 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: method of determining crystal structure of medication trimetazidine in form of tablets, which contains trimetazidine dihydrochloride, crystal filler and auxiliary substances, lies in the following: determination of crystal structure is carried out by difractometre DRON 3 with copper anticathode with irradiation λ=1.5405 E, voltage 40 kV and current intensity 40 mA for tablets with fixed dose of trimetazidine dihydrochloride 20 mg with application as crystal filler mannitol, for tablets with fixed dose of trimetazidine dihydrochloride 35 mg with application as crystal filler mannitol or calcium hydrophosphate dehydrate.

EFFECT: measured crystal structures can be used for control of production, prediction of active substance solubility and quality of medication tablets.

15 cl, 9 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a derivative of 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine of formula

and its optical isomers and pharmaceutically acceptable salts where R1 represents CH3 or CH3CH2; R2 represents H, 2-F, 2-Cl, 3-F, 3-OCN3, 3-CN, 3-CF3, 3-CONH2 or 3-SO2CH3; R3 represents H or CH3; R4 represents H or CH3; and R5 represents H; or when R4 represents CH3, R5 represents H or F. Also, the invention refers to methods for producing the compounds of formula (I) and to pharmaceutical compositions exhibiting CX3CR1 receptor antagonist properties containing the compounds of formula (I).

EFFECT: production of 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine as selective CX3CR1 receptor antagonists.

15 cl, 2 tbl, 18 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to a new acid dihydrogenphosphate of 2-(3-{6-[2-(2,4-dichlorophenyl)ethylamino]-2-methoxypyrimidine-4-yl}phenyl)-2-methylpropionic acid of formula optionally in a crystalline form exhibiting cAMP inhibitor properties. Also, the invention refers to a pharmaceutical composition.

EFFECT: compound can find application for treating the diseases associated with cell expression of prostaglandin D2 in such diseases, as allergic rhinitis, bronchial asthma, allergic conjunctivitis, etc.

3 cl, 12 dwg, 1 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, in particular, to problem of non-invasive removal of atherosclerotic deposits from main vessels. Claimed is water solution, which includes collagenase, oxypropylated β-cyclodextrin, block copolymer of ethylene- and propylene- oxide, dimethyl sulfoxide and complexone with carboxyl groups with the following component ratio, wt %: oxypropylated β-cyclodextrin - 2.0-5.5; block copolymer of ethylene oxide and propylene oxide - 0.02-2.0; dimethyl sulfoxide - 3.5-10.5; collagenase - 0.002-0.007; complexone with carboxyl groups - up to 6.5; water - the remaining part.

EFFECT: composition makes it possible to remove content of atherosclerotic deposits efficiently.

6 ex, 1 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of medicine, namely to chemical-pharmaceutical industry and deals with composition of alpha-lipoic (thioctic) acid in form of solution for infusions and to method of treating diseases selected from group, which includes alcoholic and/or diabetic polyneuropathy, coronary atherosclerosis, Botkin's disease (mild and moderate severity), liver cirrhosis, poisoning with heavy metal salts and intoxications of various etiology.

EFFECT: pharmaceutic composition possesses improved technologic properties and bioavailability, it also preserves stability in long storage.

3 cl, 1 ex, 3 tbl

FIELD: chemistry.

SUBSTANCE: invention relates to novel compounds of formula (I) or pharmaceutically acceptable salts thereof where R1 and R2 together denote a group selected form groups of formula (III-1): , where R9 denotes 1) a lower alkyl group, optionally substituted with a halogen atom or lower alkoxy group, 2) an aryl group, 3) an aralkyl group, 4) a heteroarylalkyl group, 5) a heteroaryl group, where the aryl, aralkyl, heteroarylalkyl and heteroaryl groups can be substituted with a halogen atom, lower alkyl group, optionally substituted with a lower alkoxy group or 1-3 halogen atoms, lower alkoxy group, optionally substituted with 1-3 halogen atoms, cyano group, hydroxy group, alkylsulphonyl group, cycloalkylsulphonyl group, aryl group, heteroaryl group, alkylaminocarbonyl group, alkanoyl amino group, alkyl amino group or dialkylamino group; R10 denotes a lower alkyl group, optionally substituted with 1-3 halogen atoms, or a lower alkylsulphonyl group; X9-X12 denotes a carbon atom or a nitrogen atom, where the carbon atom can be independently substituted with a lower alkyl group, optionally substituted with a halogen atom or a lower alkoxy group, lower alkoxy group, optionally substituted with a halogen atom, or a cyano group or a halogen atom; R3 denotes a) a group of formula (II-1): (ii-U where R4 and R5, taken together with a nitrogen atom, form a 5- or 6-member monocyclic ring, where the monocyclic ring may contain a substitute in form of a lower alkyl group, m1 equals 3; or b) a group of formula (II-2): , where R6 denotes a lower alkyl group or cycloalkyl group; m2 equals 1 or 2; X1-X4 all denote carbon atoms, or one of X1-X4 denotes a nitrogen atom and the rest denote carbon atoms; and where "heteroaryl" in each case relates to a 5- or 6-member aromatic ring containing 1-3 heteroatoms selected from a nitrogen atom, oxygen atom and a sulphur atom. The invention also relates to a histamine H3 receptor antagonist or inverse agonist, as well as a preventive or medicinal agent.

EFFECT: obtaining novel biologically active compounds, having histamine H3 receptor antagonist or inverse agonist activity.

11 cl, 8 ex, 1 tbl

FIELD: chemistry.

SUBSTANCE: invention relates to novel prodrugs of biologically active 2,4-pyrimidine diamine compounds with structural formula given below, hydrate, solvate and pharmaceutically acceptable salts thereof. The compounds have properties for inhibiting cascade transmission of a signal from an Fc-receptor, such as FcαRI, FcγRI, FcγRIII and FcεRI, degranulation or Syk kinase activity. Structural formula:

EFFECT: compounds can be used to treat or prevent rheumatoid arthritis and autoimmune diseases.

25 cl, 21 cl, 6 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to phytotherapy. The herbal tea contains haws, motherwort herb, hop cones, peppermint leaves, melilot herb, inula rhizomes and roots, black chokeberry fruits, centaury herb, wild strawberry leaves, melissa herb, green ginger herb, corn stigma and style, mountain ash fruits, caraway fruits in the following proportions 1:1:1:0.5:2:1:1:1:1:2:1:1:1:1 respectively.

EFFECT: use of the invention provides extended range of herbal drugs with an evident therapeutic effect for prevention and treatment of chronic heart disease.

5 ex, 3 dwg, 2 tbl

FIELD: medicine.

SUBSTANCE: in formula (I) , the ring A represents 6-members aryl or 5-6-members heteroaryl containing 1-2 heteroatoms selected from nitrogen and sulphur; Q means C3-8 cycloalkyl, 5-6-members heterocycle containing 1 heteroatom selected from oxygen, nitrogen or sulphur, C1-6 alkyl or C2-6 alkenyl; the ring T represents 5, 6, 9 or 10-members heteroaryl or 9-members heterocycle optionally additionally substituted by 1-3 heteroatoms independently selected from nitrogen or sulphur. The values of other substitutes are specified in the patent claim. Also, the invention refers to methods for preparing oxime derivatives of general formula (I), to pharmaceutical compositions containing the compound of the invention as an active ingredient and to applications of the compounds of the invention in preparing a drug.

EFFECT: compounds of the invention exhibit properties of a glucokinase activator.

33 cl, 1499 ex

FIELD: chemistry.

SUBSTANCE: invention relates to novel compounds - benzoquinone derivatives of formula (I): , where each of R1 and R2 is O-C(O)phenyl; where the phenyl is substituted with 1 substitute selected from halide, nitro, C1-C6 alkyl or C1-C6 alkoxy, and pharmaceutically acceptable salts thereof.

EFFECT: low activity of pancreatic lipase based on compounds of the said formula.

6 cl, 3 tbl, 23 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed is application of biologically active substance for production of medication for treatment of syndrome of resistance to insulin, diabetes, including type I diabetes and type II diabetes, syndrome of ovary polycystosis, treatment or reduction of probability of atheroslerosis development, arterioslerosis, obesity, hypertension, hyperlipidemia, fatty infiltration of liver, nephropathy, neuropathy or retinopathy, feet ulceration or cataracts associated with diabetes, where medication represents compound of formula , as well as corresponding treatment method, pharmaceutical composition and biologically active substance of the same purpose.

EFFECT: increase of compound activity: 75% reduction of glucose level with loading in contrast to 10% reduction for analogues known before, as well as reduction of level of triglycerides in blood serum.

17 cl, 1 dwg, 2 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to compounds of formula

wherein Q together with carbon and nitrogen atoms whereto attached forms a 5-6-members monocyclic heteroaromatic ring; or Q together with carbon and nitrogen atoms whereto attached forms a 9-10-members bicyclic heterocycle; R1 and R2 independently mean hydrogen, halogen, alkyl, alkyl substituted by one or more halogen, alkoxygroup, alkoxygroup substituted by alkoxygroup, alkylthiogroup, sulphonyl, free or etherified carboxygroup, carbamoyl, sulohamoyl, morpholinyl or pyridinyl; or R2 is absent; R3 means (C3-C6)cycloalkyl; R4 means hydrogen, halogen, lower alkyl or lowest alkyl substituted by one or more halogen; R5 means (C3-C6cycloalkyl, (C6-C10) aryl, (C3-C10)heterocyclyl or (C1-C6)alkyl optionally substituted by (C1-C6)alkoxygroup, (C3-C7)cycloalkyl, (C6-C10)aryl or (C3-C10)heterocyclyl; R6 means free or etherified carboxygroup; and n is an integer equal to 1-6; or to its enanthiomer, or a mixture of its enanthiomers, or its pharmaceutically acceptable salt. Besides, the invention refers to a method of glucokinase activation in mammals, to a method of treating pathological conditions associated with glucokinase activation in mammals and impaired glucose tolerance, as well as to a pharmaceutical composition based on these compounds and to application of said compositions for preparing a drug.

EFFECT: there are produced and described new compounds which are activators and can be used as therapeutic agents for treating the glucokinase mediated pathological conditions.

31 cl, 4 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a compound having structure

, radicals are as described in the formula of invention, as well as pharmaceutically-acceptable salt, prodrug, tautomer and stereoisomer thereof. The invention also relates to a composition, a set for modulating PPAR based on said compound, a method of treating a patient suffering from a disease or condition or at risk of a disease or condition, for which PPAR modulation is therapeutically useful.

EFFECT: novel compounds which are active towards PPAR are obtained and described.

41 cl, 622 ex, 8 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a compound of formula

where X represents OR1, SR1 or NR1R2 where R1 and R2 independently represent C1-C5 lower alkyl, and R1 and R2 in NR1R2 can form a 5-7-members ring including an O heteroatom; or to its stereoisomer, to a pharmaceutically acceptable salt, hydrate or solvate. Besides, the invention refers to a method for making thereof and to a based pharmaceutical composition exhibiting DPP-IV inhibitor activity.

EFFECT: new compounds which can find application in medicine for prevention or treatment of the DPP-IV associated diseases, such as diabetes or obesity are produced.

12 cl, 1 tbl, 2 dwg, 18 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention aims at a pharmaceutical composition in the form of a clear solution or a water mixture, a suspension or a semisolid composition containing at least one peptide compound of water solubility more than 1 mg/ml at room temperature and pH value within 4.0 to 6.0 selected from the group consisting of hGLP-1 (7-36)-NH2, as well as its analogues and derivatives, hGLP-1 (7-37)-OH, as well as its analogues and derivatives and/or exendin-4, as well as its analogues and derivatives, zinc and a solvent where less than 95 % of said peptide compound are dissolved by the solvent.

EFFECT: invention provides a long-term effect of the preparation with lower initial plasma concentrations.

20 cl, 1 dwg

FIELD: medicine.

SUBSTANCE: invention relates to field of pharmacology, medicine and food industry and deals with medicine for reduction of visceral fatty tissue accumulation, which contains compounds of formula or extract of plant Liliaceae, which includes these compounds, application of said compounds or extracts for inhibition of visceral fatty tissue accumulation as well as product on their basis.

EFFECT: invention insures efficient reduction of visceral fatty tissue accumulation.

19 cl, 2 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmacology and is intended for extension of nomenclature of herbal medications for treatment of diabetes mellitus. Medication, representing bog bilberry shoots, demonstrates activation of glucose absorption by ischemic brain in treatment of type II diabetes mellitus. Studies were Indices of glucose-tolerant test at initial level, 30, 60, 120 minutes after glucose loading, as well as level of glucosuric activity. At the background of experimental DM utilisation of glucose by ischemic brain was determined by arterial-venous difference.

EFFECT: obtained results substantiate possibility of bog bilberry shoots application in clinic.

1 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmacology and is intended for extension of nomenclature of herbal medications for treatment of diabetes mellitus (DM). Studied are properties of Vaccinium axillare Nakai shoots, Far East plant, which had not been studied before. Glucose-tolerant test, made on male rats of Wistar line with weight 200-220 g, showed reliable hypoglycemic and glucosuric action of Vaccinium axillare Nakai shoots. Hypoglycemic effect of Vaccinium axillare Nakai is also confirmed in experiment on alloxan diabetes model. It has been established that newly studied plant activates glucose utilisation by brain, aggravated by angiopathy, at the background of alloxan diabetes.

EFFECT: obtained results indicate that Vaccinium axillare Nakai shoots have hypoglycemic and glucosuric effect and that new object has advantage in comparison with Vaccinium myrtillus due to more expressed hypoglycemic action and ability to activate glucose utilisation by brain in case of DM.

1 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a method for preparing a microelement drug on the basis of an iron-dextrin complex. The method includes the following stages: mixed water-soluble iron (III) salt and one or more water-soluble salts containing other microelements, e.g., cobalt, copper, zinc, manganese and selenite, and low-molecular dextrin are neutralised before sedimentation of iron (III) hydroxide, alkalised to pH 9-11, heated up to complete resolution and neutralised with an acid. Then, membrane ultrafiltration procedure is used to purify the prepared colloidal iron-dextrin complex with microelement atoms deposited in a polymeric covalent lattice of iron (III) oxide, and to concentrate it.

EFFECT: method allows preparing high-effective high iron fixation polymicroelement drug ensuring the best effect in treating iron-deficient conditions and promoting immune system resistance.

3 cl, 2 dwg, 3 ex

Up!